Is AGXT p.Asp129His (c.385G>C) pathogenic?

AGXT p.Asp129His (c.385G>C) is classified Uncertain significance in AGXT (ClinVar, Multiple submitters, 3 submitters; last evaluated 2023-10-27). AlphaMissense: likely benign (0.1557); Ultra-rare (popmax 0.014%, nfe); Associated with primary hyperoxaluria type 1.

What condition is associated with AGXT p.Asp129His (c.385G>C)?

AGXT p.Asp129His (c.385G>C) is associated with primary hyperoxaluria type 1 (ClinVar).

How common is AGXT p.Asp129His (c.385G>C) in the general population?

AGXT p.Asp129His (c.385G>C) is ultra-rare (popmax 0.014%, nfe) (gnomAD).

How is Primary hyperoxaluria inherited?

Typically Autosomal recessive (Orphanet). A genetic counselor can assess individual risk for a family.

What do computational predictors say about AGXT p.Asp129His (c.385G>C)?

AlphaMissense predicts likely benign (score 0.1557) — an in-silico prediction, not a clinical call.

AGXT p.Asp129His

c.385G>C · rs180177212 · VCV204034

Uncertain significance Multiple submitters

Classification

Uncertain significance

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 3 submitters

AlphaMissense

likely benign

0.1557 · ACMG-weighted

gnomAD v4.1

Rare

ultra-rare (popmax 0.014%, nfe)

Missense predictors

1/3 damaging

AlphaMissense, REVEL, SaProt

Conditions

primary hyperoxaluria type 1

Computational evidence

Protein change
AlphaMissense	0.1557	likely benign
REVEL	0.687	pathogenic-leaning
SaProt	LLR -7.29	tolerated
⇒ REVEL calls this damaging; AlphaMissense and SaProt do not.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 5.3	GERP -0.11, phastCons 1
Regional constraint	o/e 1.00	unconstrained · MANE · 9,952 bp · p 0.92 · regional, not allelic
Overall
CADD	24.8	PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.014% European (non-Finnish) · 161/1,149,454 alleles

Filtering AF 0.0122% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.0115%

Overall 0.011% 171/1,555,546 alleles · ultra-rare

Ancestry group	Frequency	1 in
European (non-Finnish)grpmax	0.014%	7,139
Remaining individualsnot grpmax-eligible	0.0083%	12,055
Finnishnot grpmax-eligible	0.00675%	14,808
African / African-American	0.00136%	73,470

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: AGXT
Protein: p.Asp129His
Coding: c.385G>C
MANE Select: NM_000030
dbSNP: rs180177212
Type: single nucleotide variant
Location: chr2:240870670 (GRCh38)
Gene constraint: LOEUF 1.251 · pLI <0.01 · ClinGen HI gene assoc. with recessive phenotype (gnomAD)
Structure: AlphaFold pLDDT 98.30 · 17 PDB

Full AGXT gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

primary hyperoxaluria type 1 — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

For Primary hyperoxaluria (Orphanet):

Inheritance: Autosomal recessive
Onset: All ages
Prevalence: 1-9 / 1 000 000 (Germany)

Similar variants

AGXT p.Asp129fs Likely pathogenic ★ same residue
AGXT p.Asp129Asn Uncertain significance ★ ⚠ same residue
AGXT p.Asp129= Likely benign ★ same residue
AGXT c.358+1G>A Pathogenic ★★ same condition
AGXT c.359-2A>G Likely pathogenic ★★ same condition
AGXT c.423+1G>A Pathogenic/Likely pathogenic ★★ same condition
AGXT c.524+2T>A Likely pathogenic ★★ same condition
AGXT c.525-1G>A Pathogenic ★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/agxt-p-asp129his (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown